Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Roivant Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Roivant Sciences Ltd.'s regulatory disclosures and financial reporting.
ROIV filed a Form 144 reporting the proposed sale of $17,039,650.00 worth of 500,000 shares via the Exercise of Options Under a Registered Plan. The filing cites an intended sale date of 06/26/2026 and lists cash as the method. The excerpt also shows 500,000 shares sold during the prior three months for $17,051,141.93.
Morgan Stanley Smith Barney LLC Executive Financial Services reported an intended sale of 500,000 shares of Common stock on 06/25/2026 under an Exercise of Options Under a Registered Plan. The filing lists the sale as routed through the issuer for cash and identifies NASDAQ as the exchange.
Roivant Sciences Ltd. filed a Form 144 disclosing proposed dispositions of Common Shares under Rule 144. The filing lists 200,000 shares associated with an options exercise (grant date 04/20/2022) and shows past sales of 200,000 shares on 04/20/2026 and 200,000 shares on 05/22/2026.
Roivant Sciences Ltd. CFO Richard Pulik reported a routine share disposition tied to equity compensation. On the RSU vesting date, 2,129 common shares at $31.43 per share were withheld by the company to satisfy tax withholding obligations through a net settlement of previously granted RSUs. Following this tax-related transfer, Pulik directly holds 276,420 common shares of Roivant Sciences Ltd.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a routine tax-related share disposition. On this Form 4, 3,582 common shares were surrendered at a value of $31.43 per share to cover tax withholding tied to the vesting of previously granted RSUs. After this net settlement, she directly holds 109,782 common shares, indicating the transaction reflects compensation and tax obligations rather than an open-market sale.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a set of transactions involving company shares. He exercised stock options to acquire 200,000 Common Shares at $3.85 per share, then sold 200,000 Common Shares in an open-market transaction at a weighted average price of $30.27 per share. Separately, 34,483 Common Shares were surrendered through a net settlement to cover tax withholding obligations on vested RSUs, which is not an open-market sale. After these transactions, Venker directly holds 1,613,063 Common Shares.
Roivant Sciences Ltd. CFO Richard Pulik reported a tax-withholding share disposition related to restricted stock units (RSUs). On this event, 18,962 common shares were withheld at a value of $32.41 per share to cover tax obligations triggered by the vesting and settlement of previously granted RSUs. After this non‑market transaction, Pulik directly holds 278,549 common shares, indicating he retains a substantial equity position in the company.
Roivant Sciences Ltd. submitted a Form 144 disclosing a proposed sale of 200,000 common shares tied to an Options Exercise - Grant Date 05/22/2026. The filing lists a sale date of 05/22/2026 for those shares.
The filing also records recent sales by Eric Venker: 7,051 common shares on 02/20/2026 for $191,434.65, 200,000 common shares on 03/17/2026 for $5,648,836.44, and 200,000 common shares on 04/20/2026 for $5,917,134.05.
Roivant Sciences Ltd. outlines a broad late-stage biopharmaceutical pipeline focused on autoimmune and cardiopulmonary diseases, alongside key ownership stakes in multiple "Vants." Lead asset brepocitinib is under FDA Priority Review for dermatomyositis with a PDUFA target in the third quarter of 2026, and in Phase 3 trials for several inflammatory indications.
Immunovant is advancing IMVT-1402, a potentially best-in-class FcRn inhibitor in multiple potentially registrational studies, while discontinuing first‑generation batoclimab to concentrate resources on IMVT‑1402. Pulmovant is developing once‑daily inhaled mosliciguat for pulmonary hypertension associated with interstitial lung disease in a global Phase 2 trial.
Roivant also highlights Genevant, a majority‑owned nucleic acid delivery company whose LNP technology underpins the first FDA‑approved systemic RNA‑LNP drug and which entered a $2.25 billion global settlement with Moderna in March 2026, including $950 million due by July 2026 and a further $1.3 billion contingent on a favorable appeal ruling.
Roivant Sciences Ltd. reported fourth-quarter and full-year results for the period ended March 31, 2026, and outlined key pipeline and legal milestones. For the quarter, income from continuing operations was $355.7 million, driven largely by a $770.2 million gain from a global litigation settlement with Moderna.
For the full year, Roivant posted a $397.9 million loss from continuing operations and a non-GAAP loss of $747.7 million, reflecting heavy investment in R&D and share-based compensation. The company held $4.3 billion in cash, cash equivalents and marketable securities as of March 31, 2026, which it states supports a cash runway into profitability.
Operationally, Roivant highlighted strong preliminary IMVT-1402 data in difficult-to-treat rheumatoid arthritis, FDA Priority Review for brepocitinib in dermatomyositis, Breakthrough Therapy Designation in cutaneous sarcoidosis and rapid enrollment for mosliciguat in pulmonary hypertension associated with interstitial lung disease. The Moderna settlement totals $2.25 billion, including a $950 million non-contingent payment due in July 2026 and a contingent $1.3 billion payment tied to a Section 1498 appeal outcome.